NDAINJECTIONINJECTABLE
Approved
Sep 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Just now · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOSPHOCOL P32 is a radiopharmaceutical containing chromic phosphate labeled with phosphorus-32, administered by injection for diagnostic and therapeutic nuclear medicine applications. The product works through localized radiation delivery to target tissues. Mechanism of action and specific indications are not detailed in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating a contracting commercial footprint and likely smaller, focused brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE status indicate this is a declining product with minimal hiring and limited career advancement potential. Positions supporting PHOSPHOCOL P32 are highly specialized, defensive roles focused on market protection rather than growth.
Regulatory Affairs SpecialistRadiopharmaceutical Specialist
Worked on PHOSPHOCOL P32 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.